{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:01:51Z","timestamp":1792504911133,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vetimm.2019.109904","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T01:40:29Z","timestamp":1564191629000},"page":"109904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum"],"prefix":"10.1016","volume":"215","author":[{"given":"A.","family":"Buono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Lidbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wilson-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Dangott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Allenspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Suchodolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vetimm.2019.109904_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13547500701674063","article-title":"Serum soluble interleukin 2 receptor in human cancer of adults and children: a review","volume":"13","author":"Bien","year":"2008","journal-title":"Biomarkers"},{"key":"10.1016\/j.vetimm.2019.109904_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1208\/s12248-014-9696-2","article-title":"Workshop report: Crystal City V\u2013quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance","volume":"17","author":"Booth","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.vetimm.2019.109904_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cyto.2017.04.024","article-title":"Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis","volume":"93","author":"Buhelt","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.vetimm.2019.109904_bib0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s10620-009-0955-5","article-title":"Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)","volume":"55","author":"Cabrera","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.vetimm.2019.109904_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/S0962935193000018","article-title":"Biological significance of soluble IL-2 receptor","volume":"2","author":"Caruso","year":"1993","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.vetimm.2019.109904_bib0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ndt\/gfy018","article-title":"Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study","volume":"34","author":"Dekkema","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.vetimm.2019.109904_bib0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.05.014","article-title":"High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma","volume":"59","author":"Dlouhy","year":"2017","journal-title":"Leukemia Res"},{"key":"10.1016\/j.vetimm.2019.109904_bib0045","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00125-013-3113-8","article-title":"Plasma concentrations of soluble IL-2 receptor alpha (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients","volume":"57","author":"Downes","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.vetimm.2019.109904_bib0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/vcp.12006","article-title":"ASVCP reference interval guidelines: determination of de novo reference intervals in veterinary species and other related topics","volume":"41","author":"Friedrichs","year":"2012","journal-title":"Vet. Clin. Pathol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1939-165X.2011.00287.x","article-title":"Reference value advisor: a new freeware set of macroinstructions to calculate reference intervals with microsoft excel","volume":"40","author":"Geffre","year":"2011","journal-title":"Vet. Clin. Pathol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000486402","article-title":"Serum soluble interleukin 2 receptor level as a marker of acute rejection in pediatric kidney transplant recipients","volume":"139","author":"Hagras","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.vetimm.2019.109904_bib0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/194495a0","article-title":"Preparation of iodine-131 labelled human growth hormone of high specific activity","volume":"194","author":"Hunter","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.vetimm.2019.109904_bib0075","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1084\/jem.183.4.1587","article-title":"Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding","volume":"183","author":"Junghans","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vetimm.2019.109904_bib0080","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1172\/JCI115457","article-title":"Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue","volume":"88","author":"Kurane","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vetimm.2019.109904_bib0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/00313029109063570","article-title":"Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro","volume":"23","author":"Lai","year":"1991","journal-title":"Pathology"},{"key":"10.1016\/j.vetimm.2019.109904_bib0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jinf.2004.10.013","article-title":"Serum levels of soluble interleukin-2 receptor alpha (slL-2R alpha) as a predictor of outcome in brucellosis","volume":"51","author":"Makis","year":"2005","journal-title":"J. Infect."},{"key":"10.1016\/j.vetimm.2019.109904_bib0095","first-page":"410","article-title":"Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia","volume":"34","author":"Moon","year":"2004","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.vetimm.2019.109904_bib0100","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.vetimm.2019.109904_bib0105","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.2741\/1461","article-title":"Soluble interleukin-2 receptor in cancer","volume":"9","author":"Murakami","year":"2004","journal-title":"Front. Biosci."},{"key":"10.1016\/j.vetimm.2019.109904_bib0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1572-0241.1998.00323.x","article-title":"The circulating common gamma chain (CD132) in inflammatory bowel disease","volume":"93","author":"Nielsen","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-0-387-72005-0_30","article-title":"Serum levels of soluble HLA and IL-2R molecules in patients with urogenital chlamydia infection","volume":"601","author":"Novikov","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4236\/ojvm.2013.32027","article-title":"Soluble interleukin 2 receptor-alpha (sIL-2R\u03b1) in the peripheral blood of dogs\u2014comparison of malignant neoplasia with other diseases","volume":"3","author":"Prachar","year":"2013","journal-title":"Open J. Vet. Med."},{"key":"10.1016\/j.vetimm.2019.109904_bib0125","first-page":"8","article-title":"Relationship between serum soluble interleukin-2 receptor and renal allograft rejection: a hospital-based study in Kashmir Valley","volume":"6","author":"Rasool","year":"2015","journal-title":"Int. J. Transplant. Med."},{"key":"10.1016\/j.vetimm.2019.109904_bib0130","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.137.12.3841","article-title":"The released interleukin 2 receptor binds interleukin 2 efficiently","volume":"137","author":"Rubin","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0135","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"Rubin","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0047748","article-title":"Soluble IL-2R alpha (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice","volume":"7","author":"Russell","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vetimm.2019.109904_bib0145","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-12-38","article-title":"Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes","volume":"12","author":"Seidler","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0150","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/nprot.2006.468","article-title":"In-gel digestion for mass spectrometric characterization of proteins and proteomes","volume":"1","author":"Shevchenko","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.vetimm.2019.109904_bib0155","first-page":"3","article-title":"Physiology and its importance for reference intervals","volume":"35","author":"Sikaris","year":"2014","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.vetimm.2019.109904_bib0160","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.vetimm.2019.109904_bib0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5114\/pdia.2015.55177","article-title":"Soluble interleukin-2 receptor alpha and interleukin-2 serum levels in patients with basal cell carcinoma","volume":"33","author":"Sobjanek","year":"2016","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0170","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2460\/ajvr.1996.57.10.1417","article-title":"Development and validation of a radioimmunoassay for feline trypsin-like immunoreactivity","volume":"57","author":"Steiner","year":"1996","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.vetimm.2019.109904_bib0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-G","article-title":"The IL-2\/IL-2 receptor system: a current overview","volume":"73","author":"Taniguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.vetimm.2019.109904_bib0180","first-page":"661","article-title":"Soluble TNF and IL-2 receptors in patients with breast cancer","volume":"6","author":"Tesarova","year":"2000","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.vetimm.2019.109904_bib0185","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/jclinpath-2015-202934","article-title":"Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma","volume":"68","author":"Toji","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.vetimm.2019.109904_bib0190","first-page":"122","article-title":"Biological role of the soluble interleukin-2 receptor in sarcoidosis","volume":"34","author":"Vanmaris","year":"2017","journal-title":"Sarcoidosis Vasc. Diff."},{"key":"10.1016\/j.vetimm.2019.109904_bib0195","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1182\/blood.V126.23.4958.4958","article-title":"Clinical significance of soluble interleukin-2 receptor in patients with acute leukemia","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2019.109904_bib0200","first-page":"1445","article-title":"Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma","volume":"6","author":"Wang","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vetimm.2019.109904_bib0205","first-page":"1","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.vetimm.2019.109904_bib0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1155\/MI.2005.121","article-title":"On the role of sIL-2R measurements in rheumatoid arthritis and cancers","volume":"2005","author":"Witkowska","year":"2005","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.vetimm.2019.109904_bib0215","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R alpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242719302120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242719302120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:24:53Z","timestamp":1759044293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242719302120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":43,"alternative-id":["S0165242719302120"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2019.109904","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2019.109904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109904"}}